Evidence map›Paper›PMID 31560538›Full record

ArticleBioconjugate chemistry2019

Copper-64 Labeled PEGylated Exosomes for In Vivo Positron Emission Tomography and Enhanced Tumor Retention.

Sixiang Shi, Tingting Li, Xiaofei Wen, Sherry Y Wu, Chiyi Xiong, Jun Zhao, Victor R Lincha, Diana S Chow, Yiyao Liu, Anil K Sood and 1 more

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Long-Term Tumor-Targeting Effect ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sixiang ShiDepartment of Cancer Systems Imaging , The University of Texas MD Anderson Cancer Center , Houston , Texas 77054 , United States.ORCID 0000-0002-8354-7620
Tingting LiDepartment of Cancer Systems Imaging , The University of Texas MD Anderson Cancer Center , Houston , Texas 77054 , United States.
Xiaofei WenDepartment of Cancer Systems Imaging , The University of Texas MD Anderson Cancer Center , Houston , Texas 77054 , United States.
Sherry Y WuDepartment of Gynecologic Oncology and Reproductive Medicine , The University of Texas MD Anderson Cancer Center , Houston , Texas 77230 , United States.
Chiyi XiongDepartment of Cancer Systems Imaging , The University of Texas MD Anderson Cancer Center , Houston , Texas 77054 , United States.
Jun ZhaoDepartment of Cancer Systems Imaging , The University of Texas MD Anderson Cancer Center , Houston , Texas 77054 , United States.
Victor R LinchaDepartment of Pharmacological and Pharmaceutical Sciences , University of Houston , Houston , Texas 77024 , United States.
Diana S ChowDepartment of Pharmacological and Pharmaceutical Sciences , University of Houston , Houston , Texas 77024 , United States.
Yiyao LiuDepartment of Biophysics , University of Electronic Science and Technology of China , Chengdu , Sichuan 610054 , P. R. China.ORCID 0000-0002-7222-739X
Anil K SoodDepartment of Gynecologic Oncology and Reproductive Medicine , The University of Texas MD Anderson Cancer Center , Houston , Texas 77230 , United States.
Chun LiDepartment of Cancer Systems Imaging , The University of Texas MD Anderson Cancer Center , Houston , Texas 77054 , United States.ORCID 0000-0002-2376-4703

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Targeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BROADDUS, RUSSELL R · 2003 to 2020
$32.0M
U.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BAST, ROBERT C, SOOD, ANIL K · 2017 to 2021
$7.9M
Harnessing the power of exosomes for non-coding RNA deliveryR35CA209904 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2023
$5.0M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA098258NCI NIH HHS P50 CA217685NCI NIH HHS R35 CA209904
6 · The paper itself

Abstract

Exosomes have attracted tremendous attention due to their important role in physiology, pathology, and oncology, as well as promising potential in biomedical applications. Although great efforts have been dedicated to investigating their biological properties and applications as natural cancer drug-delivery systems, the systemic biodistribution of exosomes remains underexplored. In addition, exosome-based drug delivery is inevitably hindered by the robust liver clearance, leading to suboptimal tumor retention and therapeutic efficiency. In this study, we report one of the first examples using in vivo positron emission tomography (PET) for noninvasive monitoring of copper-64 (

Indexed as

AnimalsCell Line, TumorCopper RadioisotopesExosomesMicePolyethylene GlycolsPositron-Emission TomographyTissue DistributionCopper-64Copper RadioisotopesPolyethylene Glycols

Identifiers

PMID31560538
PMCPMC6947533

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.